通过线粒体转移进行癌细胞的帝国战略
Takamasa Ishino1, Yosuke Togashi1,2,3
1Faculty of Medicine, Department of Tumor Microenvironment, Dentistry and Pharmaceutical Sciences, Okayama University, Japan.
Molecular oncology
|October 5, 2025
概括
癌细胞积极地将线粒体捐赠给瘤微环境 (TME) 中的其他细胞. 这种转移会重编程纤维细胞,并损害抗瘤免疫力,突出癌症.
科学领域:
- 细胞生物学 细胞生物学
- 癌症生物学 癌症生物学
- 线粒体生物学 线粒体生物学
背景情况:
- 线粒体是调节细胞代谢和功能的重要器官.
- 细胞间线粒体转移是一种新发现的细胞间通信形式.
- 线粒体转移发生在瘤微环境 (TME) 中,影响瘤进展.
研究的目的:
- 研究癌细胞在TME中作为线粒体捐赠者的作用.
- 了解癌细胞衍生的线粒体如何影响周围的层状细胞和免疫细胞.
- 探索细胞间线粒体转移对瘤进展和抗瘤免疫的影响.
主要方法:
- 在TME中对线粒体转移的观察性研究.
- 从癌细胞到纤维细胞通过道化纳米管进行线粒体捐赠的分析.
- 对线粒体转移到瘤透淋巴细胞的研究.
主要成果:
- 癌细胞将线粒体捐赠给纤维细胞,从而产生与癌症相关的纤维细胞,具有增强的新陈代谢和前瘤性质.
- 癌细胞可以将线粒体转移到瘤透的淋巴细胞中,从而损害抗瘤免疫反应.
- 癌细胞充当线粒体捐赠者,重塑TME以促进瘤生长.
结论:
- 癌细胞战略性地利用线粒体捐赠来重新编程TME.
- 癌细胞的细胞间线粒体转移有助于瘤的进展和免疫规避.
- 准线粒体转移代表了癌症治疗中的潜在治疗策略.
相关概念视频
Adaptive Mechanisms in Cancer Cells
6.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.8K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Metastasis
6.3K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.3K
Cancer Cell Migration through Invadopodia
3.1K
Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
3.1K
Electron Transport Chain: Complex I and II
18.3K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
18.3K
Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K


